Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831226) titled 'Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-59 Years' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Guangzhou Patronus Biotech Co., Ltd.
Condition:
Malaria Vaccine
Intervention:
Biological: LYB014 low dose
Biological: LYB014 high dose
Biological: LYB017 low dose
Biological: LYB017 high dose
Biological: LYB027 low dose
Biological: LYB027 high dose
Recruitment Status: No...